Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data
AR Pavelic, C Wöber, F Riederer, K Zebenholzer - Cells, 2022 - mdpi.com
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …
Therapies targeting CGRP signaling for medication overuse headache
IA Koumprentziotis, DD Mitsikostas - Current Opinion in Neurology, 2022 - journals.lww.com
The available data indicate that anti-CGRP mAbs represent a good mechanism-based and
disease-specific therapeutical option with for MOH as long as detoxification and additional …
disease-specific therapeutical option with for MOH as long as detoxification and additional …
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
R Belvís, P Irimia, P Pozo-Rosich… - The Journal of …, 2021 - Springer
Background Erenumab was approved in Europe for migraine prevention in patients with≥ 4
monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access …
monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access …
Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes
J Schoenen, G Timmermans, R Nonis… - Frontiers in …, 2021 - frontiersin.org
During a 1-year compassionate use program, 156 patients with migraine self-administered a
monthly dose of erenumab 140 mg with a subcutaneous autoinjector. Main inclusion criteria …
monthly dose of erenumab 140 mg with a subcutaneous autoinjector. Main inclusion criteria …
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP (− receptor) antibodies
M Terhart, J Mecklenburg, L Neeb, LH Overeem… - The Journal of …, 2021 - Springer
Background Migraine preventive treatment with CGRP (− receptor) monoclonal antibodies
(mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German …
(mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German …
Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study …
Background Neurological conditions are highly prevalent and disabling, in particular in the
elderly. The Italian population has witnessed sharp ageing and we can thus expect a rising …
elderly. The Italian population has witnessed sharp ageing and we can thus expect a rising …
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
A Straube, P Stude, C Gaul, K Schuh… - The Journal of Headache …, 2021 - Springer
Background Erenumab, the first-in-class fully human monoclonal antibody targeting the
calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the …
calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the …
Gender differences in 3-month outcomes of Erenumab treatment—study on efficacy and safety of treatment with Erenumab in men
R Ornello, C Baraldi, S Guerzoni, G Lambru… - Frontiers in …, 2021 - frontiersin.org
Objective: We reported gender-specific data on the efficacy and safety of erenumab, a
monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor …
monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor …
Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series
T Toni, R Tamanaha, B Newman, Y Liang, J Lee… - Neurological …, 2021 - Springer
Aims Clinical trials for calcitonin gene-related peptide (CGRP) inhibitors excluded the
concomitant use of onabotulinumtoxinA; thus, there is a lack of efficacy and safety data of the …
concomitant use of onabotulinumtoxinA; thus, there is a lack of efficacy and safety data of the …
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey
A Dapkutė, J Vainauskienė, K Ryliškienė - Neurological Sciences, 2022 - Springer
Background Despite development of new therapies, migraine remains an undertreated
illness. It is important to understand patients' preferences and perceptions of using a certain …
illness. It is important to understand patients' preferences and perceptions of using a certain …